GGrantIndex
Sort

40,608 grants matching prostate cancer

Forms of prostate specific antigen and hk2 in cancer

$477,115
Scripps Research Institute · M01 · FY2004 · RR

Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach

$477,037
Conor C Lynch · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2023 · CA

Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort

$476,842
Mia Hashibe · University Of Utah · R01 · FY2022 · CA

Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort

$476,842
Mia Hashibe · University Of Utah · R01 · FY2023 · CA

Cancer Recurrence: Detection in Administrative Data, Incidence, and Costs

$476,825
Michael James Hassett · Dana-Farber Cancer Inst · R01 · FY2016 · CA

Integrin-mediated mechanisms of prostate cancer progression

$476,796
Lucia R Languino · Thomas Jefferson University · R01 · FY2020 · CA

Molecular Epidemiology of Fatal Prostate Cancer

$476,732
Sheila A Weinmann · Kaiser Foundation Research Institute · R01 · FY2006 · CA

HPV genomic structure in cervical cancer radiation response and recurrence detection

$476,719
Jin Zhang · Washington University · R37 · FY2024 · CA

Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation

$476,715
Jin Xie · University Of Georgia · R01 · FY2018 · EB

TempO-Seq Profiling of RNA Epitranscriptomic Modifications

$476,709
Bruce E. Seligmann · Biospyder Technologies, Inc. · R44 · FY2021 · HG

Implementation of evidence-based cancer early detection in Black churches

$476,695
Cheryl L Holt · Univ Of Maryland, College Park · R01 · FY2012 · CA

SOUTHWEST ONCOLOGY GROUP CA-13612

$476,677
University Of Arizona · U10 · FY2003 · CA

Bystander gene deletions in cancer: mechanisms of therapeutic opportunities and challenges

$476,578
Biplab Dasgupta · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · NS

Image Biomarker Development for TreatmentEfficacy of Prostate Cancer to the Bone

$476,542
Brian D. Ross · University Of Michigan At Ann Arbor · R01 · FY2012 · CA

MICROFLUIDIC DIAGNOSTICS FOR MONITORING OF BRAF INHIBITOR RESISTANCE IN MELANOMA

$476,399
Hsian-Rong Tseng · University Of California Los Angeles · P01 · FY2017 · CA

MICROFLUIDIC DIAGNOSTICS FOR MONITORING OF BRAF INHIBITOR RESISTANCE IN MELANOMA

$476,399
Hsian-Rong Tseng · University Of California Los Angeles · P01 · FY2016 · CA

MICROFLUIDIC DIAGNOSTICS FOR MONITORING OF BRAF INHIBITOR RESISTANCE IN MELANOMA

$476,399
Hsian-Rong Tseng · University Of California Los Angeles · P01 · FY2015 · CA

Trans-urethral ultrasound for prostate cancer therapy

$476,391
Mayo Clinic · R33 · FY2005 · CA

Development of an Optimal MRI Platform for Prostate Investigations at 7 Tesla

$476,312
Gregory John Metzger · University Of Minnesota · R01 · FY2014 · CA

Project 3: Targeting SK2/S1P Signaling for the Regulation of c-Myc and Tumor Suppression

$476,309
Carolyn D Britten · Medical University Of South Carolina · P01 · FY2020 · CA

Clinical validation of the HD-CTC fluid biopsy in early detection of lung cancer.

$476,289
Peter Kuhn · Scripps Research Institute, The · R33 · FY2013 · CA

INCREASING ACCESS TO CLINICAL AND EDUCATIONAL STUDIES

$476,184
Thomas Jefferson University · U01 · FY2004 · CA

Prognostic and Predictive Digital Tissue Image Assay for Prostate Cancer

$476,165
Anant Madabhushi · Emory University · R01 · FY2024 · CA

Clinical Protocol and Data Management

$475,992
Susanne M Arnold · University Of Kentucky · P30 · FY2025 · CA

Genetic Epidemiology of Prostate Cancer

$475,868
Fred Hutchinson Cancer Research Center · R01 · FY2004 · CA